Dr. Porter’s primary focus within his role is to further develop and support growth of the Current Good Manufacturing Practice (CGMP) Facility.
Dr. Porter comes has 15 years of experience in research and development (R&D) of vaccines and biopharmaceuticals. Additionally, Dr. Porter has a proven track record of advancing novel candidates and production platforms from discovery to the clinic including: cell culture based viral vaccines, next-generation reverse genetics platforms, CHO expressed recombinant protein vaccines and RNA vaccines. With senior level management experience in both academia and industry, Dr. Porter brings a unique perspective and ability to provide and implement high quality management of the new CGMP facility. As Head of Drug Substance R&D at Glaxosmithkline (GSK), Dr. Porter led a global technical development team responsible for antigen manufacturing processes development for the GSK Vaccine product portfolio. His R&D expertise includes production and characterization of vaccines, gene therapy vectors, nucleic acid and recombinant protein therapeutics.